정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1773 | Recruiting | Covid-19, Hospitalized, PatIents, Nasafytol | Coronavirus Infection | Drug: NASAFYTOL® Drug: FULTIUM® -D3 800 |
Not Applicable | Tilman S.A., Artialis | INDUSTRY | 50 | All | 18 Years | Delta Hospital, Brussels, Belgium |
| 1772 | Not yet recruiting | COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 | Pneumonia, Viral | Drug: Nivolumab | Phase 2 | Dr Gerry Gin Wai Kwok, The University of Hong Kong | OTHER | 15 | All | 18 Years | |
| 1771 | Withdrawn | COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older | Coronavirus Disease 2019 (COVID-19) | Biological: SARS-CoV-2 mRNA Vaccine (CVnCoV) Biological: Quadrivalent influenza vaccine (QIV) Other: Placebo |
Phase 3 | Bayer, CureVac AG | INDUSTRY | 0 | All | 60 Years | |
| 1770 | Recruiting | COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement | Transmission | Biological: BCG Biological: Placebo |
Phase 4 | University of Campinas, Brazil, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Instituto de Infectologia Emilio Ribas, Pontificia Universidade Catolica de Campinas, PUC-Campinas, Faculty of Medicine of Ribeirao Preto (FMRP-USP), Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil, Federal University of Sao Paulo, State Hospital Dr. Leandro Franceschini, Sumare, Unicamp, Paulinia Municipal Hospital | OTHER | 1000 | All | 18 Years | Hospital das Clinicas Unicamp, Campinas, SP, Brazil |
| 1769 | Not yet recruiting | COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7 | Covid19 | Combination Product: Tomeka® Drug: "Vernonia amygdalina" |
Not Applicable | Guyguy K Tshima, MD, Centre Medical de Kinshasa (CMK) | OTHER | 2000 | All | 15 Years ~ 65 Years | Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the |
| 1768 | Not yet recruiting | COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 | Cancer | Biological: Spikevax | Phase 4 | Jules Bordet Institute, Roche Pharma AG | OTHER | 525 | All | 18 Years | Institut Jules Bordet, Brussels, Belgium |
| 1767 | Recruiting | COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients | SARS-CoV 2 | Drug: Povidone-Iodine Nasal Spray and Gargle Drug: Povidone-Iodine Nasal Spray and Gargle Drug: Povidone-Iodine Nasal Spray and Gargle |
Phase 2 | Alexandra Kejner | OTHER | 300 | All | 18 Years ~ 99 Years | University of Kentucky, Lexington, Kentucky, United States |